The Network for Excellence in Health Innovation finds potential areas of innovation and then tries to eliminate the obstacles to those ideas so its members can achieve the triple aim, according to Susan Dentzer, president and CEO of The Network for Excellence in Health Innovation.
The Network for Excellence in Health Innovation finds potential areas of innovation and then tries to eliminate the obstacles to those ideas so its members can achieve the triple aim, according to Susan Dentzer, president and CEO.
Transcript (slightly modified)
What are your key goals as the new president and CEO of the Network for Excellence in Health Innovation?
So, at NEHI, Network for Excellence in Health Innovation, we really do take seriously this notion of innovation. We’re a policy institute, a think tank, sitting within a membership organization, and we look for ways to engage our broad membership — payers, providers, patient groups, biopharmaceutical companies, and others – in innovating, looking for areas where we could innovate around the triple aim, and then in particular, solving problems that get in the way of that innovation.
Taking the obstacles out, or at least beginning to understand what are the obstacles that stand in the way of innovation, whether they are inherent to systems or organizations or whether they’re related to policies at the federal, state, or local level. And then, identify what needs to happen to remove those obstacles and actually allow the innovations that have this amazing potential to improve health or improve care or create more sustainable costs, allow those to flourish.
So we are already engaged in activities that further those goals and we’ll be doing more and more of those in the future. Looking for ways where we can solve problems in healthcare by bringing the sectors together and brainstorming how we can achieve those results.
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More